Scholarlink

<p>The path from a&#xa0;clinical study to guideline-based treatment is often long and shaped by the interaction of numerous stakeholders. Scientific institutions, industrial and academic sponsors, national and international regulatory authorities and medical professional societies all contribute to translating scientific findings into evidence-based treatment recommendations. Clinical trials represent the central instrument for generating clinical evidence and form the foundation for regulatory decisions and for the development of modern treatment strategies. Using selected examples from ophthalmology this article illustrates how diverse the developmental pathways of new therapies can be, from the first clinical evidence to the integration into clinical guidelines. In addition, it highlights how clinical studies continue to support guideline development and enrich everyday clinical practice beyond the initial approval of new drugs. In this way, it becomes clear how clinical studies shape the entire translational process, from scientific innovation and regulatory evaluation to the establishment of treatment in guidelines and routine clinical care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Wegweisende Studien in der Augenheilkunde – von der klinischen Studie zur Leitlinientherapie

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月8日

查看全文
  • Immanuel Philipp Seitz,
  • Melanie Ziegler,
  • Nadine Kahle,
  • Barbara Wilhelm,
  • Tobias Peters

摘要

The path from a clinical study to guideline-based treatment is often long and shaped by the interaction of numerous stakeholders. Scientific institutions, industrial and academic sponsors, national and international regulatory authorities and medical professional societies all contribute to translating scientific findings into evidence-based treatment recommendations. Clinical trials represent the central instrument for generating clinical evidence and form the foundation for regulatory decisions and for the development of modern treatment strategies. Using selected examples from ophthalmology this article illustrates how diverse the developmental pathways of new therapies can be, from the first clinical evidence to the integration into clinical guidelines. In addition, it highlights how clinical studies continue to support guideline development and enrich everyday clinical practice beyond the initial approval of new drugs. In this way, it becomes clear how clinical studies shape the entire translational process, from scientific innovation and regulatory evaluation to the establishment of treatment in guidelines and routine clinical care.